Tumor Biology

, Volume 37, Issue 1, pp 1261–1269 | Cite as

miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB

  • Yiping Du
  • Mingxia Zhu
  • Xin Zhou
  • Zebo Huang
  • Jun Zhu
  • Jing Xu
  • Gongming Cheng
  • Yongqian Shu
  • Ping Liu
  • Wei Zhu
  • Tongshan Wang
Original Article

Abstract

Drug resistance of cancer cells can be regulated by the dysregulated miRNAs, and sustained NFκB activation also plays an important role in tumor resistance to chemotherapy. Here, we sought to investigate whether there was a correlation between miR-20a and the NFκB pathway to clarify the effects that miR-20a exerted on gastric cancer (GC) chemoresistance. We found that miR-20a was significantly upregulated in GC plasma and tissue samples. In addition, it was upregulated in GC plasma and tissues from patients with cisplatin-resistant gastric cancer cell line SGC7901/cisplatin (DDP). And the upregulation of miR-20a was concurrent with the downregulation of NFKBIB (also known as IκBβ) as well as upregulation of p65, livin, and survivin. The luciferase activity suggested that NFKBIB was the direct target gene of miR-20a. Transfection of miR-20a inhibitor could increase NFKBIB level; downregulate the expression of p65, livin, and survivin; and lead to a higher proportion of apoptotic cells in SGC7901/DDP cells. Conversely, ectopic expression of miR-20a dramatically decreased the expression of NFKBIB; increased the expression of p65, livin, and survivin; and resulted in a decrease in the apoptosis induced by DDP in SGC7901 cells. Taken together, our findings suggested that miR-20a could promote activation of the NFκB pathway and downstream targets livin and survivin by targeting NFKBIB, which potentially contributed to GC chemoresistance.

Keywords

miR-20a NFκB NFKBIB Cisplatin resistance 

Abbreviations

miRNAs

microRNAs

DDP

Cisplatin

Notes

Acknowledgments

The authors are grateful to the fund support by the National Natural Science Foundation of China (grant number 81201705 and 81201796) and the Natural Science Foundation of Jiangsu Province (grant number BK2012442).

Conflicts of interest

None

Supplementary material

13277_2015_3921_MOESM1_ESM.pdf (286 kb)
ESM 1 (PDF 285 kb)

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMedGoogle Scholar
  2. 2.
    Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26.CrossRefPubMedGoogle Scholar
  3. 3.
    Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205(2):275–92.CrossRefPubMedGoogle Scholar
  4. 4.
    Nakagawa Y, Sedukhina AS, Okamoto N, Nagasawa S, Suzuki N, Ohta T, et al. NF-kappaB signaling mediates acquired resistance after PARP inhibition. Oncotarget. 2015;6(6):3825–39.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res. 2010;70(17):6804–14.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Loschmann N, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011;2:e243.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lin X, Zhang X, Wang Q, Li J, Zhang P, Zhao M, et al. Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-kappaB signaling pathway in a human breast cancer cell line. Neoplasma. 2012;59(3):248–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMedGoogle Scholar
  9. 9.
    Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2014;33(3):378–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Shang Y, Zhang Z, Liu Z, Feng B, Ren G, Li K, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014;33(25):3267–76.CrossRefPubMedGoogle Scholar
  11. 11.
    Sui C, Meng F, Li Y, Jiang Y. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. J Transl Med. 2015;13:132.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Fang L, Li H, Wang L, Hu J, Jin T, Wang J, et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 2014;5(10):2974–87.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013;32(36):4284–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Eberle KE, Sansing HA, Szaniszlo P, Resto VA, Berrier AL. Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB. PLoS One. 2011;6(6):e21496.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2012;69(3):723–31.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127(11):2520–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhao DS, Chen Y, Jiang H, Lu JP, Zhang G, Geng J, et al. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure. Cardiovasc Pathol. 2013;22(6):444–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 2012;33(7):1294–301.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhao S, Yao D, Chen J, Ding N, Ren F. MiR-20a promotes cervical cancer proliferation and metastasis in vitro and in vivo. PLoS One. 2015;10(3):e0120905.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Fan X, Liu Y, Jiang J, Ma Z, Wu H, Liu T, et al. miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim Biophys Sin. 2010;42(5):318–24.CrossRefPubMedGoogle Scholar
  21. 21.
    Huang G, Nishimoto K, Zhou Z, Hughes D, Kleinerman ES. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 2012;72(4):908–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Xiong Y, Zhang L, Kebebew E. MiR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1. PLoS One. 2014;9(5):e96103.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M, et al. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One. 2012;7(10):e46367.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Li X, Zhang Z, Yu M, Li L, Du G, Xiao W, et al. Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). Int J Mol Sci. 2013;14(8):16226–39.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chai H, Liu M, Tian R, Li X, Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin. 2011;43(3):217–25.CrossRefPubMedGoogle Scholar
  26. 26.
    Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132(3):344–62.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang ZH, Chen H, Guo HC, Tong HF, Liu JX, Wei WT, et al. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Int J Oncol. 2011;39(5):1123–31.PubMedGoogle Scholar
  28. 28.
    Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 2010;1805(2):167–80.PubMedGoogle Scholar
  29. 29.
    Xia JT, Chen LZ, Jian WH, Wang KB, Yang YZ, He WL, et al. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-kappaB signaling. J Transl Med. 2014;12:33.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res. 2007;13(20):5995–6000.CrossRefPubMedGoogle Scholar
  31. 31.
    Zhou R, Hu G, Gong AY, Chen XM. Binding of NF-kappaB p65 subunit to the promoter elements is involved in LPS-induced transactivation of miRNA genes in human biliary epithelial cells. Nucleic Acids Res. 2010;38(10):3222–32.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yiping Du
    • 1
  • Mingxia Zhu
    • 2
  • Xin Zhou
    • 2
  • Zebo Huang
    • 2
  • Jun Zhu
    • 3
  • Jing Xu
    • 2
  • Gongming Cheng
    • 4
  • Yongqian Shu
    • 2
  • Ping Liu
    • 2
  • Wei Zhu
    • 2
  • Tongshan Wang
    • 2
  1. 1.Department of OncologyThe First People’s Hospital of Kunshan Affiliated with Jiangsu UniversitySuzhouPeople’s Republic of China
  2. 2.Department of OncologyFirst Affiliated Hospital of Nanjing Medical UniversityNanjingPeople’s Republic of China
  3. 3.Department of Radiation OncologyJiangsu Cancer HospitalNanjingPeople’s Republic of China
  4. 4.Department of General SurgeryFirst Affiliated Hospital of Nanjing Medical UniversityNanjingPeople’s Republic of China

Personalised recommendations